Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers
- Authors: Tkachuk VN1, Al-Shukri SK.1, Tkachuk IN1, Mosoyan MS1
-
Affiliations:
- Issue: No 6 (2009)
- Pages: 25-27
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277649
- ID: 277649
Cite item
Full Text
Abstract
Pharmacotherapy of prostatic adenoma is based in present-day practice primarily on two basic groups of medicines - inhibitors of 5alpha-reductase and blockers of alpha1-adrenoreceptors. Our trial included 98 patients with prostatic adenoma aged 59-79 years given combined treatment with finasteride (inhibitor of 5alpha-reductase) made in Hungary (prosteride®, Gedeon Richter) and an uroselective blocker of alpha1-adrenoreceptors sonisin® (Gedeon Richter, Hungary). Prosteride® was given for 12 months, sonisine® - for the first 6 months of combined treatment. Positive results were achieved in 97(99%) of 98 patients. After 12-month combined treatment symptoms of the disease reduced by IPSS from 17.9 ± 1.8 to 3.9 ± 0.9 points, Qmax rose from 8.8 ± 0.3 to 14.6 ± 0.3, residual urine volume diminished from 91.7 ± 8.5 to 31.7 ± 4.4, the size of the prostate reduced from 72.4 ± 2.9 to 50.6 ± 3.7, quality of life improved 2-fold. Combined administration of finasteride (prosteride) and alpha1-adrenoblocker tamsulosine (sonisine) meet three principles of pharmacotherapy of prostatic adenoma: prevents progression of the disease and surgical treatment, relieves symptoms and improves quality of life.
References
- Ткачук В. Н. Медикаментозное лечение больных доброкачественной гиперплазией предстательной железы.
- Рекомендации совещания совета экспертов по лечению аденомы предстательной жедезы. - М., 2008.
- Montorsi F., Moncada I. Safety and tolerability of treatment for BPH. Eur. Urol. Suppl. 2006; 5: 1005-1009.
- Лоран О. Б., Лукьянов И. В., Пушкарь Д. Ю. и др. Комбинированная терапия финастеридом и альфа-1-адреноблокатором у больных доброкачественной гиперплазией простаты. Клин. фармакол. и тер. 2004; 13 (5): 1-6.
- Ткачук В. Н., Аль-Шукри С. Х., Лукьянов А. Э. и др. Комбинированное применение ингибиторов 5альфа-редуктазы и блокаторов альфа-1-адренорецепторов у больных доброкачественной гиперплазией простаты. Урология 1998; 3: 5-8.
- Богданов А. Б., Лукьянов И. В., Велиев Е. И. Комбинированное применение доксазозина и финастерида при лечении аденомы предстательной железы. Урология 2006; 5: 59-63.
- McConnel J. D. For the MTOPS Research Group. The long term effect of doxazosin, finasteride an combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349: 2385-2396.
- Siami P. Combination therapy with dutasteridi and tamsulosin in men with moderate-to-serve BPH: the CombAT. Clin. Trials 2007; 28 (6): 770-779.
- Baldwin K., Ginsberg P., Roehrborn C., Hakaway R. Discontinuation of alfa-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hypeplasia. Urology 2001; 58: 203-209.
Supplementary files
